SLRX vs IQV

IQVIA Holdings Inc.

(IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate IQVIA Holdings Inc. (IQV) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, IQVIA Holdings Inc.

(IQV) delivered a total return of -23. 8%, compared to -100. 0% for Salarius Pharmaceuticals, Inc. (SLRX). Over 10 years, the gap is even starker: IQV returned +166. 5% versus SLRX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Salarius Pharmaceuticals, Inc.

(SLRX) is the lower-risk stock at 1. 10β versus IQVIA Holdings Inc. 's 1. 33β — meaning IQV is approximately 21% more volatile than SLRX relative to the S&P 500. On balance sheet safety, Salarius Pharmaceuticals, Inc. (SLRX) carries a lower debt/equity ratio of 15% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: IQVIA Holdings Inc.

grew EPS 4. 7% year-over-year, compared to -1522. 7% for Salarius Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IQVIA Holdings Inc.

(IQV) is the more profitable company, earning 8. 3% net margin versus 0. 0% for Salarius Pharmaceuticals, Inc. — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus 0. 0% for SLRX. At the gross margin level — before operating expenses — IQV leads at 26. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Salarius Pharmaceuticals, Inc.

(SLRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10)). Both have compounded well over 10 years (SLRX: -100. 0%, IQV: +166. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.